Skip to content
Syncom Formulations logo

Syncom Formulations

SYNCOMF NSE
₹20.32 down 0.01 (0.05%)
Market Cap
₹1,910 Cr
P/E
22.58

Syncom Formulations (SYNCOMF) share price was ₹20.33 at the 28 Oct 2026 close; market capitalisation ₹1,911 Cr; P/E (TTM) 22.59; sector Healthcare. The share price rose 22.5% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 7.4% year on year to ₹125.5 Cr and net profit rose 57.6% year on year to ₹24.9 Cr (compared with Jun 2025). Promoters held 50.57% of Syncom Formulations in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 63/100 (Good) as of 28 Oct 2026.

Close 28 Oct 2026 ₹20.33 +3.60 +21.52% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹1,910 Cr
P/E (TTM)
22.58
EBITDA
₹109 Cr
Return on Equity
18.42%
Debt to Equity
0
Book Value
₹4.41
EPS (TTM)
₹0.90
52W High
₹27.49
52W Low
₹10.21

Price-based figures as of 29 Oct 2026, 10:46 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,766.7035.054,23,891 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,655.0087.632,56,310 Cr15.290.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,610.5072.381,75,369 Cr9.540.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,188.00108.101,18,220 Cr22.310.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,181.3026.291,17,835 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,338.7034.671,11,739 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,364.8032.701,10,257 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Syncom Formulations (this company)
₹20.3222.581,910 Cr4.610.49%18.42%23.78%531 Cr86 Cr
Median 8 companies₹1,565.7534.861,18,028 Cr4.840.55%14.56%18.45%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

63 Good
Overall score

Data confidence 100/100

Category scores

Quality Good 57
Returns, margins, earnings quality 22% weight
Valuation Strong 71
Cheap vs sector & own history 24% weight
Growth Poor 12
Sales & profit trajectory 9% weight
Financial Health Strong 89
Solvency, leverage, coverage 9% weight
Momentum Strong 79
Trend strength, vol-adjusted 12% weight
Ownership Strong 66
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company has reduced debt.
  • Company is almost debt free.

Weaknesses

1
  • Earnings include an other income of Rs.32.8 Cr.

Technical Indicators

Oscillators

Bullish

Bearish
2
Neutral
3
Bullish
4

Overall

Bullish

Bearish
7
Neutral
3
Bullish
9

Moving Averages

Neutral

Bearish
5
Neutral
0
Bullish
5

Growth Rate

Revenue Growth
7.9% lower than 3Y

change over 1 year

Net Income Growth
54.66% higher than 3Y

change over 1 year

Cash Flow Change
148%

change over 1 year

EBITDA Margin Change
40.93%

change over 1 year Operating margin 21% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
59
62
63
73
87
101
127
148
117
121
115
134
125
Expenses
53
56
57
64
76
90
112
131
101
103
93
113
99
Operating Profit
6
6
7
9
10
12
15
17
16
19
21
21
26
OPM %
10%
10%
11%
12%
12%
12%
11%
12%
14%
15%
18%
16%
21%
Other Income
2
4
4
3
1
4
4
7
6
5
5
14
8
Interest
1
1
1
1
0
0
0
0
0
0
0
0
0
Depreciation
1
1
1
1
1
1
1
1
1
1
1
2
2
PBT
6
8
9
9
10
15
17
23
20
22
25
33
32
Tax %
27%
24%
25%
27%
24%
25%
24%
24%
22%
25%
25%
25%
23%
Net Profit
4
6
6
7
8
11
13
18
16
17
19
25
25
EPS (₹)
0.05
0.07
0.07
0.07
0.08
0.12
0.14
0.19
0.17
0.18
0.2
0.26
0.26
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
173
184
185
159
187
206
245
216
222
257
461
486
495
Expenses
155
167
168
147
175
189
207
196
202
229
407
409
407
Operating Profit
18
17
16
12
12
17
38
20
20
28
54
77
87
OPM %
11%
9%
9%
7%
6%
8%
16%
9%
9%
11%
12%
16%
18%
Other Income
1
3
3
4
5
5
7
12
15
13
17
31
33
Interest
0
0
0
0
0
1
0
2
3
5
1
1
1
Depreciation
3
3
3
4
4
4
4
4
5
5
5
7
7
PBT
16
16
16
12
13
17
41
26
27
32
65
101
112
Tax %
38%
36%
33%
28%
12%
18%
28%
24%
24%
26%
24%
24%
—
Net Profit
10
10
11
9
11
14
29
20
20
24
49
76
85
EPS (₹)
0.13
0.13
0.14
0.11
0.14
0.18
0.37
0.23
0.21
0.25
0.52
0.81
0.9
Div. Payout %
16%
15%
15%
0%
0%
0%
0%
13%
0%
0%
0%
12%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
78
78
78
78
78
78
79
86
94
94
94
94
Reserves
22
31
36
44
55
68
109
136
162
192
246
318
Borrowings
6
6
12
12
9
2
62
58
83
72
4
1
Other Liabilities
31
61
48
37
32
33
42
28
38
33
66
116
Total Liabilities
138
175
175
171
173
181
292
308
377
392
410
529
Fixed Assets
46
46
85
89
89
93
91
94
91
120
125
184
CWIP
0
5
0
1
0
0
0
6
26
0
0
0
Investments
6
23
1
2
2
1
11
43
64
66
93
109
Other Assets
85
101
89
79
83
87
189
165
196
206
192
237
Total Assets
138
175
175
171
173
181
292
308
377
392
410
529
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
24
17
-2
4
6
-2
16
10
-6
23
58
Investing
1
-23
-8
-2
2
2
-75
-27
-45
84
-18
-51
Financing
1
-2
-2
-2
0
-7
72
8
35
-15
-68
-3
Net Cash Flow
2
-1
6
-6
7
1
-5
-2
1
63
-63
4
Free Cash Flow
-3
16
9
-8
10
4
-5
5
-10
-14
13
47
CFO/EBITDA
32
176
128
13
66
61
24
113
86
6
70
105
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
66
91
91
87
81
77
112
114
124
132
85
81
Inventory Days
34
43
29
37
37
39
51
51
53
49
49
81
Days Payable
63
130
92
75
57
49
66
36
52
33
52
96
Cash Conversion Cycle
37
4
27
49
61
67
96
129
124
148
81
66
Working Capital Days
84
40
45
75
74
88
28
33
-4
51
95
85
ROCE %
16%
15%
14%
9%
9%
12%
21%
11%
10%
10%
19%
25%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Syncom Formulations insights

63 extracted metrics + investor summaries across FY11–FY27.

Shareholding Pattern

FIIs2.22%Promot.50.57%Others4.83%Public42.37%As ofSep 2026

Documents

Frequently Asked Questions about Syncom Formulations

What does Syncom Formulations (India) Ltd do?
Established in the year 1995, Syncom Formulations is a global pharmaceutical company that manufactures and markets a broad range of healthcare products. The company is a generic pharmaceutical player operating in more than 15 countries worldwide having more than 400 products registered.[1]
Where is Syncom Formulations (India) Ltd (SYNCOMF) listed?
Syncom Formulations (India) Ltd trades as SYNCOMF on the NSE and under code 524470 on the BSE.
Which sector does Syncom Formulations (India) Ltd belong to?
Syncom Formulations (India) Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd has a market capitalisation of ₹1,910 Cr as of 29 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd trades at a PE ratio of 22.58 as of 29 Oct 2026, on earnings per share of ₹0.9, against a book value of ₹4.41 per share.
What is the 52-week high and low of Syncom Formulations (India) Ltd?
Over the last 52 weeks Syncom Formulations (India) Ltd has traded between ₹10.21 and ₹27.49 as of 29 Oct 2026.
Does Syncom Formulations (India) Ltd pay dividends?
Syncom Formulations (India) Ltd has a dividend yield of 0.49%.
What is the Return on Equity (ROE) of Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd reported a return on equity of 18.42%. Its debt-to-equity ratio is 0.00.

Company Information

Established in the year 1995, Syncom Formulations is a global pharmaceutical company that manufactures and markets a broad range of healthcare products. The company is a generic pharmaceutical player operating in more than 15 countries worldwide having more than 400 products registered.[1]

Website syncomformulations.com
CEO Mr. Ankit Kedarmal Bankda
Employees 744
Listed 2022-11-18
Face Value ₹ 1
Shares Outstanding 94,00,00,000

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SYNCOMF.md for Syncom Formulations (India) Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month